Blenrep Multiple Myeloma NHS England Rollout Makes UK a World First in Blood Cancer Treatment England has become the first country in the world to make GSK's belantamab mafodotin, marketed as Blenrep, available to multiple myeloma patients through a national health...
Life science news 20 April 2026: A landmark pancreatic cancer breakthrough, record-breaking biotech IPO, major UK investment announcements and a surge in FDA approvals define a momentous week for the global life science industry. Revolution Medicines reported on 13...
When US and Israeli military operations against Iran began on 28 February 2026, the consequences for global energy markets were immediate and predictable. What was less widely anticipated was the scale of the disruption now rippling through the life sciences sector....
UK Government's Life Sciences Large Investment Portfolio: A New Era for British Life Science The United Kingdom's life sciences sector received a significant policy boost on 14 April 2026 when the government formally announced the Life Sciences Large Investment...
The UK is currently navigating a silent epidemic that threatens not only our collective physical well-being but also our national productivity and the long-term sustainability of our healthcare infrastructure. Musculoskeletal (MSK) conditions now impact nearly one in...
Life science news 13 April 2026: A record-breaking wave of M&A, an escalating GLP-1 pricing war and major FDA approvals define a landmark week for the global life science industry. Gilead Sciences announced on 7 April its acquisition of Munich-based antibody-drug...
The life science sector encompassing pharmaceuticals, biotechnology, medical technologies, diagnostics and related services is evolving rapidly. Success in this industry no longer rests solely on scientific discovery. Increasingly it depends on the right talent,...
A landmark milestone in global health has been reached as the antimalarial drug Coartem Baby has received approval from the Swiss regulator Swissmedic. It is the first treatment specifically designed for newborns and very young infants suffering from malaria. Bridging...
Danish pharmaceutical leader Novo Nordisk has made a dramatic late entry into the takeover race for United States biotech Metsera, challenging Pfizer’s earlier agreement and sparking a fierce bidding war in one of the most competitive areas of the life sciences...
London, Oxford and Cambridge have long been the heartlands of the UK life sciences sector, but other regions across the country are now rapidly emerging as centres of innovation. The Midlands, the North of England, Scotland and Northern Ireland are developing strong...
The Crown Estate has completed the acquisition of Harwell East, a 221 acre site adjacent to the Harwell Science and Innovation Campus in Oxfordshire. The development could deliver up to 4.5 million square feet of laboratory, research, manufacturing and office space,...
A new multi cancer blood test developed by the United States biotechnology company Grail has demonstrated in North America the ability to detect a wide range of cancers, including many for which no screening programmes exist, at an early and potentially treatable...
Amazon is gearing up to roll out prescription kiosks inside One Medical clinics in Los Angeles beginning December 2025. These in office machines will allow patients to collect common prescription medications such as antibiotics, inhalers, and treatments for high blood...
Eli Lilly & Company is doubling down on U.S. investment, unveiling a series of ambitious plans to expand its domestic pharmaceutical manufacturing infrastructure. These efforts come amid mounting political pressure to reshore drug production and rising competition...
In late September 2025, former U.S. President Donald J. Trump revived a series of controversial health claims and policy proposals concerning women especially pregnant women and children, triggering sharp pushback from medical experts, public health authorities, and...
The NHS in England is leading the world as the first healthcare system to introduce a pioneering ‘trojan horse’ therapy for patients with blood cancer, offering the potential to delay disease progression nearly three times longer than current treatment options....